Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4784104
Max Phase: Preclinical
Molecular Formula: C48H69N9O9S2
Molecular Weight: 980.27
Molecule Type: Unknown
Associated Items:
ID: ALA4784104
Max Phase: Preclinical
Molecular Formula: C48H69N9O9S2
Molecular Weight: 980.27
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC1(C)CN2C(CS/C(N)=N\[C@H]3CC[C@H](CNC(=O)COCC(=O)NCCCCNC(=O)COCC(=O)N[C@@H]4CC[C@@]5(O)[C@H]6Cc7ccc(O)c8c7[C@@]5(CCN6CC5CC5)[C@H]4O8)CC3)=CSC2=N1
Standard InChI: InChI=1S/C48H69N9O9S2/c1-46(2)28-57-33(27-68-45(57)55-46)26-67-44(49)53-32-10-7-29(8-11-32)20-52-39(61)24-64-22-37(59)50-16-3-4-17-51-38(60)23-65-25-40(62)54-34-13-14-48(63)36-19-31-9-12-35(58)42-41(31)47(48,43(34)66-42)15-18-56(36)21-30-5-6-30/h9,12,27,29-30,32,34,36,43,58,63H,3-8,10-11,13-26,28H2,1-2H3,(H2,49,53)(H,50,59)(H,51,60)(H,52,61)(H,54,62)/t29-,32-,34-,36-,43+,47+,48-/m1/s1
Standard InChI Key: MJZIMFHRLDKHOO-RKTVTGNMSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 980.27 | Molecular Weight (Monoisotopic): 979.4660 | AlogP: 2.25 | #Rotatable Bonds: 21 |
Polar Surface Area: 241.77 | Molecular Species: BASE | HBA: 15 | HBD: 7 |
#RO5 Violations: 3 | HBA (Lipinski): 18 | HBD (Lipinski): 8 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 10.09 | CX Basic pKa: 9.64 | CX LogP: -0.09 | CX LogD: -3.55 |
Aromatic Rings: 1 | Heavy Atoms: 68 | QED Weighted: 0.05 | Np Likeness Score: 0.05 |
1. Ma H,Wang H,Li M,Barreto-de-Souza V,Reinecke BA,Gunta R,Zheng Y,Kang G,Nassehi N,Zhang H,An J,Selley DE,Hauser KF,Zhang Y. (2020) Bivalent Ligand Aiming Putative Mu Opioid Receptor and Chemokine Receptor CXCR4 Dimers in Opioid Enhanced HIV-1 Entry., 11 (11): [PMID:33214847] [10.1021/acsmedchemlett.0c00444] |
Source(1):